State of Alaska Department of Revenue Invests $2.04 Million in Avantor, Inc. (NYSE:AVTR)

State of Alaska Department of Revenue bought a new position in shares of Avantor, Inc. (NYSE:AVTR - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 78,972 shares of the company's stock, valued at approximately $2,043,000.

Several other institutional investors have also bought and sold shares of the stock. Versant Capital Management Inc increased its holdings in shares of Avantor by 2,003.6% during the second quarter. Versant Capital Management Inc now owns 1,157 shares of the company's stock worth $25,000 after buying an additional 1,102 shares in the last quarter. Blue Trust Inc. increased its holdings in Avantor by 1,830.3% during the 2nd quarter. Blue Trust Inc. now owns 1,467 shares of the company's stock valued at $31,000 after purchasing an additional 1,391 shares in the last quarter. UMB Bank n.a. acquired a new stake in Avantor during the 3rd quarter valued at $49,000. GAMMA Investing LLC raised its position in Avantor by 89.9% in the 3rd quarter. GAMMA Investing LLC now owns 2,715 shares of the company's stock valued at $70,000 after purchasing an additional 1,285 shares during the last quarter. Finally, ORG Partners LLC boosted its stake in Avantor by 5,773.0% in the second quarter. ORG Partners LLC now owns 5,873 shares of the company's stock worth $122,000 after purchasing an additional 5,773 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company's stock.

Avantor Trading Down 0.3 %

AVTR stock traded down $0.06 during midday trading on Friday, hitting $22.31. 6,445,696 shares of the company's stock were exchanged, compared to its average volume of 6,441,791. Avantor, Inc. has a one year low of $17.46 and a one year high of $28.00. The stock's fifty day moving average price is $25.20 and its 200-day moving average price is $24.17. The company has a market cap of $15.18 billion, a PE ratio of 48.50, a price-to-earnings-growth ratio of 2.71 and a beta of 1.33. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.05 and a current ratio of 1.54.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on AVTR. UBS Group lowered their target price on Avantor from $30.00 to $29.00 and set a "buy" rating for the company in a research note on Tuesday, October 8th. Wells Fargo & Company dropped their target price on shares of Avantor from $30.00 to $28.00 and set an "overweight" rating for the company in a research note on Monday, October 28th. Morgan Stanley increased their price target on shares of Avantor from $28.00 to $29.00 and gave the company an "overweight" rating in a research note on Monday, July 29th. Royal Bank of Canada reissued an "outperform" rating and issued a $34.00 target price on shares of Avantor in a research note on Thursday, September 26th. Finally, Citigroup downgraded shares of Avantor from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $30.00 to $23.00 in a research note on Wednesday, July 10th. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $27.57.

Insider Transactions at Avantor

In other Avantor news, CAO Steven W. Eck sold 3,525 shares of Avantor stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $25.06, for a total value of $88,336.50. Following the transaction, the chief accounting officer now owns 29,544 shares of the company's stock, valued at approximately $740,372.64. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.50% of the stock is currently owned by insiders.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.